| Recruiting | Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years O NCT07204457 | EyeGene Inc. | Phase 2 / Phase 3 |
| Recruiting | Azithromycin for Meningococcal Carriage NCT06618534 | Emory University | Phase 2 |
| Unknown | Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Dis NCT05981599 | Poitiers University Hospital | — |
| Unknown | A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region NCT05212935 | Federico II University | — |
| Recruiting | Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With NCT04875819 | Thomas Benfield | Phase 4 |
| Completed | Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Ro NCT03547271 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. NCT04236960 | Walvax Biotechnology Co., Ltd. | Phase 1 |
| Completed | Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children NCT03476135 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanc NCT03378258 | Belfast Health and Social Care Trust | — |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers NCT02955797 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 NCT03077438 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to NCT02919293 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Completed | Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea NCT02864927 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate NCT02842853 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Year NCT02842866 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Hea NCT02640404 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine NCT02752906 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults NCT03798574 | University of Adelaide | — |
| Completed | Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federa NCT02699840 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Year NCT02633787 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects NCT02591290 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Stud NCT02500511 | JN-International Medical Corporation | — |
| Completed | Investigating Meningococcal Vaccines in Adults NCT02398396 | University of Oxford | N/A |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddle NCT03205358 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) NCT02569632 | UCSF Benioff Children's Hospital Oakland | Phase 4 |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adoles NCT02199691 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Va NCT01897402 | JN-International Medical Corporation | Phase 2 |
| Completed | Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older NCT01732627 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis NCT02041663 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese NCT01519713 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Men NCT01482052 | JN-International Medical Corporation | Phase 1 |
| Completed | Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial V NCT01239043 | Sanofi | Phase 2 |
| Completed | Regulation of Mucosal Immune Response to Systemic MenB Vaccine NCT00774384 | University Hospitals Bristol and Weston NHS Foundation Trust | Phase 2 |
| Completed | Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-mo NCT00937521 | Novartis Vaccines | Phase 2 |
| Completed | Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® V NCT00862277 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Ro NCT00721396 | Novartis Vaccines | Phase 2 |
| Completed | Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization NCT02712177 | CHU de Quebec-Universite Laval | — |
| Completed | Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children NCT00616421 | Novartis Vaccines | Phase 3 |
| Completed | Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C C NCT00625677 | Public Health England | Phase 4 |
| Completed | Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers NCT00626327 | Novartis Vaccines | Phase 3 |
| Terminated | B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors NCT00465582 | University Hospital, Rouen | — |
| Completed | Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ NCT00874549 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults NCT00474487 | Novartis Vaccines | Phase 3 |
| Completed | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolesce NCT00450437 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia NCT00444951 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection NCT00450632 | University Hospital, Rouen | — |
| Completed | Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Co NCT00197808 | Public Health England | Phase 4 |
| Completed | Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® NCT00850603 | Sanofi Pasteur, a Sanofi Company | Phase 4 |